These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Rose JW; Burns JB; Bjorklund J; Klein J; Watt HE; Carlson NG Neurology; 2007 Aug; 69(8):785-9. PubMed ID: 17709711 [TBL] [Abstract][Full Text] [Related]
11. [Superiority of interferon beta-1b in comparison with interferon beta-1a in multiple sclerosis. 2 years outcomes reveal that clinical advantages increase over time]. Krankenpfl J; 2001; 39(10-12):332-4. PubMed ID: 11858146 [No Abstract] [Full Text] [Related]
12. What can be learned from open direct comparative trials in multiple sclerosis? Khan O J Neurol Sci; 2009 Feb; 277 Suppl 1():S25-8. PubMed ID: 19200861 [TBL] [Abstract][Full Text] [Related]
13. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466 [TBL] [Abstract][Full Text] [Related]
14. [Emerging new therapies for relapsing remitting multiple sclerosis]. Anis S; Achiron A Harefuah; 2014 Nov; 153(11):658-62, 687, 686. PubMed ID: 25563027 [TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS. Cohen JA; Rovaris M; Goodman AD; Ladkani D; Wynn D; Filippi M; Neurology; 2007 Mar; 68(12):939-44. PubMed ID: 17372130 [TBL] [Abstract][Full Text] [Related]
16. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831 [TBL] [Abstract][Full Text] [Related]
17. The efficacy of glatiramer acetate in beta-interferon-intolerant MS patients. Vallittu AM; Peltoniemi J; Elovaara I; Kuusisto H; Färkkilä M; Multanen J; Erälinna JP Acta Neurol Scand; 2005 Oct; 112(4):234-7. PubMed ID: 16146492 [TBL] [Abstract][Full Text] [Related]
18. [Beta-interferon clinical trials using MRI in patients with multiple sclerosis]. Lebrun C Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 1):761-7. PubMed ID: 11677396 [TBL] [Abstract][Full Text] [Related]
19. Effect of dose and frequency of interferon beta-1a administration on clinical and magnetic resonance imaging parameters in relapsing-remitting multiple sclerosis. Cocco E; Marchi P; Floris G; Mascia MG; Deriu M; Sirca A; Mamusa E; Lai M; Mura M; Mallarini G; Marrosu MG Funct Neurol; 2006; 21(3):145-9. PubMed ID: 17049133 [TBL] [Abstract][Full Text] [Related]
20. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis patients treated with interferon beta: implications for clinical trials. Río J; Nos C; Tintoré M; Borrás C; Galán I; Comabella M; Montalban X Ann Neurol; 2002 Oct; 52(4):400-6. PubMed ID: 12325067 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]